Search PubMed⌕ Search

PubMed · 2688560

[Prostatic cancer].

Abstract

The incidence of prostatic cancer has been increasing and will probably increase more in Japan in the future, although it may not be probable that the incidence become high as in the western countries. Carcinoma of the prostate gland is one of cancers in which main treatment modality is hormonal manipulation. It is evident through epidemiological study that the development of prostatic cancer is associated with environmental factors such as dietary or sexual life styles which may influence on the hormonal milieu. In animal models aging and androgens are indispensable factors when inducing prostatic cancer. Thus the mechanism of hormone dependency in prostatic cancer should be elucidated to consolidate the basis of its hormonal therapy. It is shown in in vivo or in vitro experiments that the hormonal action is mediated by several growth factors. However, this must be investigated when androgens or growth factors play their roles during the process of carcinogenesis. While the main therapy of prostatic cancer is hormonal it is generally accepted that a radical means to treat prostatic cancer is solely total excision of the prostate gland when cancer is confined to the prostate. Hormone therapy is conservative principally, but is only available means now for treating patients with advanced prostatic cancer. In order to obtain more effective hormonal manipulation, the mechanism of hormone dependency must be understood. We need more effective antiandrogenic agents with lesser adverse effects. The final goal in the treatment of prostatic cancer is in its eradication. Therefore, it is urgently necessary to establish multidisciplinary treatment which includes surgery, hormonal manipulation, chemotherapy, radiation and immunotherapy for the eradication of advanced prostatic cancer.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

O Yoshida, K Oishi, Y Arai, H Mori. 1989. [Prostatic cancer].. https://pubmed.ncbi.nlm.nih.gov/2688560/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

TNF-alpha-related apoptosis-inducing ligand decoy receptor DcR2 is targeted by androgen action in the rat ventral prostate.

The apoptotic cell death process in the prostate is known to be under the control of androgens. Tumor necrosis factor-alpha (TNF-alpha)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF-alpha family of cytokines, known to induce apoptosis upon binding to its death domain-containing receptors, DR4/TRAIL-R1 and DR5/TRAIL-R2. Two additional TRAIL receptors, DcR1/TRAIL-R3 and DcR2/TRAIL-R4, lack functional death domains and act as decoy receptors for TRAIL. In this study, we examined whether TRAIL and cellular receptors expression was targeted by androgens during the apoptotic cell death process in the hormone sensitive ventral prostate. The role of androgens was investigated using two sets of experiment. (1) Androgen deprivation associated with an apoptotic process resulted in a decrease in DcR2 mRNA and protein expression in the ventral prostate 3 days after castration. Testosterone administration to castrated adult rats prevented the decrease in DcR2 mRNA and protein levels in the ventral prostate. In contrast, DcR2 expression was modified, neither in the dorsolateral nor in the anterior prostate following castration. No changes were observed in DR4, DR5, DcR1, and TRAIL mRNA and protein levels in prostate after castration. (2) A specific decrease in DcR2 expression was observed in the ventral prostate after treatment of rats with the anti-androgen flutamide. Together, the present results suggest that testosterone specifically controls DcR2 expression in the adult rat ventral prostate. Androgen withdrawal, by reducing DcR2 expression, might leave the cells vulnerable to cell death signals generated by TRAIL via its functional receptors.

Androgen Antagonists↗

Identification of steroid derivatives that function as potent antiandrogens.

We have hypothesized that some steroid derivatives bind to the androgen receptor (AR) with very low androgenic activity and therefore potentially function as better AR antagonists than clinically used antiandrogens, such as flutamide. Indeed, we previously found such a compound, 3beta-acetoxyandrosta-1,5-diene-17-one ethylene ketal (ADEK), with some estrogenic activity. Here we report the identification of 2 additional steroid derivatives, 3beta-hydroxyandrosta-5,16-diene (HAD) and androsta-1,4-diene-3,17-dione-17-ethylene ketal (OAK), as new potent antiandrogens. Like ADEK, HAD and OAK could interrupt androgen binding to the AR and suppress both dihydrotestosterone- and androstenediol-induced transactivations of wild-type and mutant ARs in prostate cancer cells. These 2 compounds also inhibited prostate-specific antigen expression in LNCaP as well as growth of different AR-positive prostate cancer cell lines stimulated by androgen. Significantly, HAD and OAK had only marginal agonist effects, as compared to hydroxyflutamide. More importantly, in contrast to ADEK, OAK was shown to possess marginal estrogenic activity. These results strengthen our hypothesis and suggest that selective steroid derivatives could be potent antiandrogenic drugs with less unfavorable effects for the treatment of prostate cancer.

Androgen Antagonists↗

Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity.

BACKGROUND: Various studies have implicated the androgen receptor (AR) in the progression of androgen-dependent human prostate cancer cells to androgen-independent and androgen-insensitive phenotypes, but the exact role of AR in progression is unclear. METHODS: To mimic the clinical situation and test the role of AR in progression, we cultured androgen-dependent LNCaP 104-S prostate tumor cells in the presence of the antiandrogen Casodex (bicalutamide) to derive resistant (CDXR) clones. In a second step, we cultured CDXR cells in the presence of the androgen R1881, which generated androgen- and Casodex-insensitive (IS) cells. These cells were then characterized with regard to AR function and the effect of ectopic AR expression or AR knockdown on androgen sensitivity. RESULTS: CDXR cells showed increased AR expression and transcriptional activity. CDXR cell proliferation was unaffected by Casodex but was repressed by androgen in vitro and in vivo. IS cells, on the other hand, had greatly reduced AR expression and activity compared to CDXR cells. Knockdown of AR expression in CDXR cells produced cells that were insensitive to androgen. Conversely, re-expression of AR in IS cells regenerated cells that were repressed by androgen. Knockdown of AR expression in 104-S cells produced cells that remained stimulated by androgen, while overexpression of AR in 104-S cells generated an androgen-repressed phenotype but did not confer androgen-independent growth. CONCLUSIONS: Increased AR expression determines whether prostate cancer cells are repressed by androgen, but is not required for androgen independence. These results may have implications for anti-AR therapy for prostate cancer.

Androgen Antagonists↗